-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On December 21, the CDE official website indicated that the listing application of Roche vedotin for injection (Polatuzumab vedotin) is planned to be included in the priority review for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Vibotuzumab is a first-in-class anti-CD79b ADC, which is composed of CD79 targeting monoclonal antibody Polatuzumab, cleavable linker and small molecule drugs
Vibotuzumab mechanism of action
Vibotuzumab was first approved by the FDA in June 2019 (trade name: Polivy), combined with bendamustine + Rituxan (rituximab) for the treatment of relapse or refractory that has received at least two previous treatments Adult patients with curative (R/R) diffuse large B-cell lymphoma (DLBCL)
A previous phase Ib/II clinical trial of Vibotuzumab evaluated the efficacy of the drug in 80 patients with relapsed or refractory DLBCL
In August of this year, the pivotal Phase III POLARIX trial of Vibotuzumab combined with R-CHP for the first-line treatment of DLBCL reached its primary endpoint
